Federal Circuit Rules Against Owl Pharma In Patent Dispute Over Prostate Cancer Drug
Lupron Depot, made by plaintiff Tap Holdings Inc., is a sustained-release prostate cancer treatment. Tap sued Owl in November 1999 after Owl completed an Abbreviated New Drug Application with the Food and Drug Administration to create a generic version of Lupron Depot.
In U.S. District Court for the Northern District of Ohio, Owl claimed the Tap patents were invalid, not...
To view the full article, register now.